240 related articles for article (PubMed ID: 16418753)
1. Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial.
Gadde KM; Yonish GM; Wagner HR; Foust MS; Allison DB
Int J Obes (Lond); 2006 Jul; 30(7):1138-42. PubMed ID: 16418753
[TBL] [Abstract][Full Text] [Related]
2. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
3. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
4. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women.
Gadde KM; Parker CB; Maner LG; Wagner HR; Logue EJ; Drezner MK; Krishnan KR
Obes Res; 2001 Sep; 9(9):544-51. PubMed ID: 11557835
[TBL] [Abstract][Full Text] [Related]
5. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
[TBL] [Abstract][Full Text] [Related]
6. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.
Kopelman P; Bryson A; Hickling R; Rissanen A; Rossner S; Toubro S; Valensi P
Int J Obes (Lond); 2007 Mar; 31(3):494-9. PubMed ID: 16953261
[TBL] [Abstract][Full Text] [Related]
7. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
Wang Y; Zheng Y; Du Y; Song DH; Shin YJ; Cho SC; Kim BN; Ahn DH; Marquez-Caraveo ME; Gao H; Williams DW; Levine LR
Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
[TBL] [Abstract][Full Text] [Related]
8. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
[TBL] [Abstract][Full Text] [Related]
9. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.
Jain AK; Kaplan RA; Gadde KM; Wadden TA; Allison DB; Brewer ER; Leadbetter RA; Richard N; Haight B; Jamerson BD; Buaron KS; Metz A
Obes Res; 2002 Oct; 10(10):1049-56. PubMed ID: 12376586
[TBL] [Abstract][Full Text] [Related]
10. Zonisamide for weight loss in obese adults: a randomized controlled trial.
Gadde KM; Franciscy DM; Wagner HR; Krishnan KR
JAMA; 2003 Apr; 289(14):1820-5. PubMed ID: 12684361
[TBL] [Abstract][Full Text] [Related]
11. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
[TBL] [Abstract][Full Text] [Related]
12. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
[TBL] [Abstract][Full Text] [Related]
13. The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults.
Mhurchu CN; Poppitt SD; McGill AT; Leahy FE; Bennett DA; Lin RB; Ormrod D; Ward L; Strik C; Rodgers A
Int J Obes Relat Metab Disord; 2004 Sep; 28(9):1149-56. PubMed ID: 15311218
[TBL] [Abstract][Full Text] [Related]
14. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
[TBL] [Abstract][Full Text] [Related]
15. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial.
Zelissen PM; Stenlof K; Lean ME; Fogteloo J; Keulen ET; Wilding J; Finer N; Rössner S; Lawrence E; Fletcher C; McCamish M;
Diabetes Obes Metab; 2005 Nov; 7(6):755-61. PubMed ID: 16219020
[TBL] [Abstract][Full Text] [Related]
16. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial.
Anderson JW; Schwartz SM; Hauptman J; Boldrin M; Rossi M; Bansal V; Hale CA
Ann Pharmacother; 2006 Oct; 40(10):1717-23. PubMed ID: 16940406
[TBL] [Abstract][Full Text] [Related]
17. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.
Newcorn JH; Kratochvil CJ; Allen AJ; Casat CD; Ruff DD; Moore RJ; Michelson D;
Am J Psychiatry; 2008 Jun; 165(6):721-30. PubMed ID: 18281409
[TBL] [Abstract][Full Text] [Related]
18. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
20. Body fat loss achieved by stimulation of thermogenesis by a combination of bioactive food ingredients: a placebo-controlled, double-blind 8-week intervention in obese subjects.
Belza A; Frandsen E; Kondrup J
Int J Obes (Lond); 2007 Jan; 31(1):121-30. PubMed ID: 16652130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
